Stanford Cancer Institute Directory
Immunology & Immunotherapy of Cancer Profiles
Showing 11 - 20 of 32
Professor of Medicine (Immunology and Rheumatology), Emeritus
Dr. Fathman is an example of a clinician scientist who has developed a clear vision for implementation of translational research. He has over 300 publications, many of them in the top peer-reviewed journals including Science, Nature, Cell, Journal of Experimental Medicine, JCI, Immunity, Nature Medicine and Nature Immunology. Among Dr. Fathman’s seminal contributions to his field, is the initial cloning of CD4 T lymphocytes while he was a member of the Basel Institute for Immunology. The use of soft agar seeding of activated cells had allowed the cloning of what are now called hybridomas and drove the field monoclonal antibody production. Using this same technology, Dr. Fathman was able to clone allo-reactive T lymphocytes. Dr. Fathman left Basel and became an Associate Professor of Immunology at Mayo Medical School in 1977. There, along with one of his postdoctoral fellows, he adapted the soft agar cloning technology to clone antigen specific CD4 T cells for the first time. The ability to study single T cell specificities allowed rapid advancement in understanding the components of the ternary complex for T cell activation and led Dr. Fathman to identify trans-complementing MHC Class 2 products used in antigen presentation before the biochemical two chain nature of MHC Class 2 products was described. Shortly thereafter, he was the first to identify “idiotypic structures“ on cloned CD4 T cells predating the identification of the T cell receptor for antigen by molecular biological techniques. Dr. Fathman moved from Mayo to Stanford in 1981 and continued his studies on T cell clones, initially identifying the “shared epitope” on HLA Class 2 molecules in RA patients. As a new faculty member at Stanford, he expanded his studies to examine animal models of autoimmunity. The initial observation that led to his studies on the use of monoclonal antibodies to treat animal models of autoimmunity came from the observation that immune unresponsiveness could be induced in mice by the use of anti-CD4 antibodies at the time of antigen immunization. Subsequently he was the first to use anti-CD4 antibodies to block allograft transplant rejection and was the first to use peptides of an autoantigen (myelin basic peptide), to induce a state of “anergy” in mice to ameliorate disease. Initially, anti-CD4 antibody was used to block progression to diabetes in NOD mice. Many subsequent publications were linked to his NOD colony including several seminal observations on pathophysiology, immunotherapy, and gene expression. One major finding was the identification of a gene, DEAF-1, expressed in pancreatic lymph nodes whose non-canonical splice variant was involved in defective non-thymic mechanisms for inducing or maintaining peripheral tolerance in NOD and in human T1D. More recently he has used gene expression studies of peripheral blood cells from type one diabetes (T1D) patients and relatives to demonstrate a gene expression signature of risk of disease and of disease progression in T1D. He is currently developing a novel therapeutic approach to the treatment of autoimmune and allergic diseases by targeting the endogenous regulatory T cell to "turn up" its activity to prevent or treat these inflammatory diseases.
George D. Smith Professor in Molecular and Genetic Medicine and Professor of Pathology and of Genetics
The Mary Hewitt Loveless, M.D. Professor in the School of Medicine and Professor of Pathology and of Microbiology and Immunology
Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Dr. Laura Johnston currently serves as the Clinical Director and Clinic Chief of the Blood & Marrow Transplantation Division and specializes in Graft Versus Host Disease (GVHD), exploring prevention and treatment of acute and chronic GVHD via clinical trials. She conducts and develops clinical research trials in allogeneic and autologous hematopoietic cell transplantation (HCT) for hematologic malignancies: acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), myeloproliferative disease, non-Hodgkin lymphoma (NHL), Hodgkin disease, myelodysplasia and aplastic anemia.
Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Dr. Lowsky has been an academic clinician and medical researcher in hematopoietic cell transplantation for 20 years and has broad experience and expertise in the field. He has designed, written, implemented and participated in single and multi-center federally-funded clinical trials; and has served on the Stanford IRB and SRC for cancer-oriented clinical trials for over 10 years.
Professor of Pediatrics (Hematology/Oncology) and of Medicine
Crystal L Mackall MD is Endowed Professor of Pediatrics and Internal Medicine at Stanford University. She serves as Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, Leader of the Cancer Immunology and Immunotherapy Program at Stanford and Director of the Parker Institute for Cancer Immunotherapy at Stanford. During her tenure as Head of the Immunology Section and Chief of the Pediatric Oncology Branch, NCI, she built an internationally recognized translational research program spanning basic studies of T cell homeostasis and tumor immunology, and clinical trials of immune based therapies for cancer. Her work is credited with identifying an essential role for the thymus in human T cell regeneration and discovering IL-7 as the master regulator of T cell homeostasis. She has led numerous cutting edge and first-in-human and first-in-child clinical trials spanning dendritic cell vaccines, cytokines, and adoptive immunotherapy using NK cells and genetically modified T cells. Her group was among the first to demonstrate impressive activity of CD19-CAR in pediatric leukemia and recently demonstrated impressive activity of a second CAR targeting CD22.. Dr. Mackall’s clinical trials are notable for the incorporation of deep biologic endpoints that further our understanding of the basis for success and failure of the agent under study. She has published over 175 manuscripts and serves in numerous leadership positions, including Leader of the NCI Pediatric Cancer Immunotherapy Trials Network, co-Leader of the St. Baldrick’s-StandUp2Cancer Pediatric Dream Team. She is Board Certified in Pediatrics and Internal Medicine.
Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Research focus in hematopoietic stem cell transplantation and Treg cell immunotherapy, with an emphasis on the treatment of graft-versus-host disease as well as immune tolerance induction for transplantation and autoimmunity.